13:30 Welcome and introduction (D. Betticher, Fribourg)
NSCLC, early and locally advanced disease, diagnosis, therapies (S. Peters, Lausanne)
13:35 Developments in radiotherapy for stage I-III NSCLC (D. De Ruysscher, Maastricht)
13:55 Surgical standards for mediastinal lymph nodes dissection: guidelines, realities, and prospects (P. van Schil, Antwerp)
14:15 Chemotherapy, targeted therapy and/or immunotherapy in stage III disease (D. Betticher, Fribourg)
14:35 Case presentations of locally advanced diseases, the role of chemotherapy/surgery vs radio-chemotherapy (P. van Schil, T. Krüger, S. Zimmermann, D. Betticher, D. De Ruysscher)
15:35 Current trial landscape in stage III incl. SAKK 16/14 / ETOP NICOLAS (S. Rothschild, Basel)
15:45 Coffee break
Biology and Pathology of lung cancer (R. Stahel, Zürich)
16:15 Advances in Pathology and Molecular Biology of NSCLC (L. Bubendorf, Basel)
16:45 The evolving field of EGFR and ALK inhibition: controversies (M. Edelman, Albuquerque)
17:15 Rare mutations in NSCLC and their treatments (O. Gautschi, Luzern)
Lung cancer screening (R.Stahel, Zürich)
17:45 Lung cancer screening - Pro (W. Weder, Zürich)
18:05 Lung cancer screening - Contra (L. Nicod, Lausanne)
18:25 Lung cancer screening - Discussion
18:30 Adjourn
Saturday 28th January 2017
Immunotherapy (D. Betticher, Fribourg)
08:00 State of the art across thoracic malignancies (incl. case presentation) (S. Peters, Lausanne)
08:45 Immunotherapy, in combination, first or second line? (incl. case presentation) (E. Felip, Barcelona)
09:30 Coffee break
Oligometastatic disease (R. Stahel, Zürich)
10:00 Oligometastatic disease, in addition to systemic therapy
- the role of surgery (P. van Schil, Antwerp)
- the role of radiotherapy (D. De Ruysscher, Maastricht)
11:00 Case presentations of 3 difficult cases, in order that all the experts can report on their way to treat (including liquid bioppsy, adjuvant therapies, etc) (A. Curioni, S. Rotschild, T. Krüger)